F023 Great Debates in Medical Dermatology
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will highlight the experiences of leaders in our field as they discuss the challenges involved with caring for sick patients. There is much to learn in medical dermatology and many of the management strategies we employ in clinical practice lack evidence. This session focus will be on complex conditions including neutrophilic dermatoses, SJS/TEN, and psoriasis with an emphasis on "big picture" challenges in dermatology, such as cost-concoius practice. Our expert panel will debate and discuss how they approach these conditions and the evidence supporting their management.
LEARNING OBJECTIVES
Formulate an evidence-based approach to patients with complex skin conditions and identify how "lumping" versus "splitting" can improve diagnosis and management.
Analyze the costs of dermatologic care in patients with complex skin conditions.
Summarize expert consensus in the management of complex medical dermatology patients.
SCHEDULE
9:00 PM
Introduction
Bridget Shields, MD, FAAD
9:10 PM
Psoriasis
Aaron Mangold, MD, FAAD
9:15 PM
Psoriasis
Arash Mostaghimi, MD, MPH, FAAD
9:20 PM
Debate and Panel Discussion
9:45 PM
Introduction
Bridget Shields, MD, FAAD
9:50 PM
SJS/TEN
Karolyn Wanat, MD, FAAD
9:55 PM
SJS/TEN
Robert Micheletti, MD, FAAD
10:00 PM
Debate and Panel Discussion
10:25 PM
Introduction
Bridget Shields, MD, FAAD
10:30 PM
Neutrophilic Dermatoses
Misha Rosenbach, MD, FAAD
10:35 PM
Neutrophilic Dermatoses
Dirk Michael Elston, MD, FAAD
10:40 PM
Debate and Panel Discussion
10:50 PM
Q&A
SPEAKERS
Dirk Michael Elston, MD, FAAD
Aaron Mangold, MD, FAAD
Robert Micheletti, MD, FAAD
Arash Mostaghimi, MD, MPH, FAAD
Misha Rosenbach, MD, FAAD
Bridget Shields, MD, FAAD
Karolyn Wanat, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); clarivate – Consultant(Grants/Research Funding); Corbus Pharmaceuticals – Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Momenta Pharmaceuticals, Inc. – Advisory Board(Honoraria); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); PHLECS – Advisory Board(Honoraria); Priovant – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Solgenix, Inc. – Investigator(Grants/Research Funding);
Robert Micheletti, MD, FAAD
Acelyrin – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); InflaRx – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Arash Mostaghimi, MD, MPH, FAAD
3Derm Systems – Consultant(Fees); AbbVie – Consultant(Fees); ACOM – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Speaker(Fees); Concert Pharmaceuticals – Consultant(Fees), Investigator(Grants/Research Funding); Digital Diagnostics – Consultant(Fees); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding); Equillium, Inc. – Consultant(Fees); Figure 1 Beauty, Inc. – Advisory Board(Stock); hims – Advisory Board(Stock); Incyte Corporation – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Fees), Consultant(Fees);
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria);
Bridget Shields, MD, FAAD
No financial relationships exist with ineligible companies.
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.